An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs V 270 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 21 Jun 2010 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2007 New trial record.